Femcon Fe is a drug owned by Allergan Pharmaceuticals International Ltd. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 06, 2019. Details of Femcon Fe's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6667050 | Chewable oral contraceptive |
Apr, 2019
(5 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Femcon Fe's patents.
Latest Legal Activities on Femcon Fe's Patents
Given below is the list of recent legal activities going on the following patents of Femcon Fe.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| File Marked Found | 20 Jan, 2016 | US6667050 (Litigated) |
| File Marked Found | 17 Dec, 2015 | US6667050 (Litigated) |
| Change in Power of Attorney (May Include Associate POA) Critical | 30 Apr, 2010 | US6667050 (Litigated) |
| Correspondence Address Change Critical | 29 Apr, 2010 | US6667050 (Litigated) |
| Patent Issue Date Used in PTA Calculation Critical | 23 Dec, 2003 | US6667050 (Litigated) |
| Recordation of Patent Grant Mailed Critical | 23 Dec, 2003 | US6667050 (Litigated) |
| Issue Notification Mailed Critical | 04 Dec, 2003 | US6667050 (Litigated) |
| Receipt into Pubs | 14 Nov, 2003 | US6667050 (Litigated) |
| Application Is Considered Ready for Issue Critical | 13 Nov, 2003 | US6667050 (Litigated) |
| Receipt into Pubs | 07 Oct, 2003 | US6667050 (Litigated) |
US patents provide insights into the exclusivity only within the United States, but Femcon Fe is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Femcon Fe's family patents as well as insights into ongoing legal events on those patents.
Femcon Fe's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Femcon Fe's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 06, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Femcon Fe Generic API suppliers:
Ethinyl Estradiol; Norethindrone is the generic name for the brand Femcon Fe. 16 different companies have already filed for the generic of Femcon Fe, with Barr having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Femcon Fe's generic
Alternative Brands for Femcon Fe
Femcon Fe which is used for contraception., has several other brand drugs in the same treatment category and using the same active ingredient (Ethinyl Estradiol; Norethindrone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apil |
| |||||||||||
| Bayer Hlthcare |
| |||||||||||
| Evofem Inc |
| |||||||||||
| Organon |
| |||||||||||
| Teva Branded Pharm |
| |||||||||||
| Wyeth Pharms Inc |
| |||||||||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Ethinyl Estradiol; Norethindrone. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Apil |
| |
| Teva Branded Pharm |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Ethinyl Estradiol; Norethindrone, Femcon Fe's active ingredient. Check the complete list of approved generic manufacturers for Femcon Fe
About Femcon Fe
Femcon Fe is a drug owned by Allergan Pharmaceuticals International Ltd. It is used for contraception. Femcon Fe uses Ethinyl Estradiol; Norethindrone as an active ingredient. Femcon Fe was launched by Apil in 2003.
Approval Date:
Femcon Fe was approved by FDA for market use on 14 November, 2003.
Active Ingredient:
Femcon Fe uses Ethinyl Estradiol; Norethindrone as the active ingredient. Check out other Drugs and Companies using Ethinyl Estradiol; Norethindrone ingredient
Treatment:
Femcon Fe is used for contraception.
Dosage:
Femcon Fe is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.035MG;0.4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |